| gptkbp:instanceOf | gptkb:chemical_compound gptkb:ergoline_derivative
 gptkb:dopamine_agonist
 
 | 
                        
                            
                                | gptkbp:approvedBy | 1988 (US) 
 | 
                        
                            
                                | gptkbp:ATCCode | N04BC02 
 | 
                        
                            
                                | gptkbp:brand | Permax Prascend
 
 | 
                        
                            
                                | gptkbp:CASNumber | 66104-23-2 
 | 
                        
                            
                                | gptkbp:contraindication | cardiac valvulopathy 
 | 
                        
                            
                                | gptkbp:discoveredBy | gptkb:Eli_Lilly_and_Company 
 | 
                        
                            
                                | gptkbp:eliminationHalfLife | 27 hours 
 | 
                        
                            
                                | gptkbp:excretion | urine 
 | 
                        
                            
                                | gptkbp:hasMolecularFormula | C19H26N2S 
 | 
                        
                            
                                | gptkbp:hasSMILES | CN(C)CCCN1C2=CC=CC=C2C3=C1C=CC(=C3)SCC 
 | 
                        
                            
                                | gptkbp:legalStatus | withdrawn in US and EU 
 | 
                        
                            
                                | gptkbp:mechanismOfAction | dopamine receptor agonist 
 | 
                        
                            
                                | gptkbp:metabolism | hepatic 
 | 
                        
                            
                                | gptkbp:molecularWeight | 314.49 g/mol 
 | 
                        
                            
                                | gptkbp:pregnancyCategory | Not recommended 
 | 
                        
                            
                                | gptkbp:PubChem_CID | gptkb:CHEMBL1423 47807
 43513
 
 | 
                        
                            
                                | gptkbp:routeOfAdministration | oral 
 | 
                        
                            
                                | gptkbp:sideEffect | fibrosis valvular heart disease
 
 | 
                        
                            
                                | gptkbp:synonym | Pergolida Pergolide mesylate
 
 | 
                        
                            
                                | gptkbp:UNII | QX9Y1J6CZ1 
 | 
                        
                            
                                | gptkbp:usedFor | gptkb:Parkinson's_disease equine Cushing's disease
 pituitary pars intermedia dysfunction in horses
 
 | 
                        
                            
                                | gptkbp:usedInVeterinaryMedicine | yes 
 | 
                        
                            
                                | gptkbp:withdrawn | gptkb:European_Union gptkb:United_States
 2007
 
 | 
                        
                            
                                | gptkbp:bfsParent | gptkb:N04BB 
 | 
                        
                            
                                | gptkbp:bfsLayer | 8 
 | 
                        
                            
                                | https://www.w3.org/2000/01/rdf-schema#label | Pergolide 
 |